We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Merge Healthcare Signs Agreement with Radiology Detector Distributor in China

By HospiMedica International staff writers
Posted on 01 Dec 2009
Merge Healthcare (Milwaukee, WI, USA), a medical imaging solutions provider, reported that its Merge China business unit has signed a distribution agreement with Pangaea Technology, Ltd. More...
(Hong Kong SAR, China), a distributor of charged couple device (CCD) detectors, which are an economic alternative to digital detectors, for digital radiography (DR) systems in the Greater China area. Pangaea will provide the Chinese DR market with a bundled system consisting of Merge CIE (Cedara Image Enhancement) and CCD through their eight offices and wide distribution channels in China.

"After the healthcare reform plan was announced in China early this year, we recognized that there would be large demand for economical DR solutions in the rural healthcare market. Many local modality manufacturers have since switched their product lines to address a cost conscious, big volume market. We believe the CCD sensor and Merge CIE is a solution that will fit into this market perfectly,” explained Richard Fung, CEO and president of Pangaea (HK) Limited, which is the parent company of Pangaea China. "During this preliminary stage of work with Merge China, our customers are quite happy and satisfied with the enhanced images filtered by CIE, the flexibility of the tuning tools, and the timely response through Merge's local technical team. With Merge's extensive knowledge and advanced technologies in the medical imaging domain, we expect to dramatically grow our CCD shipment during 2010, and we are looking at the healthcare industry as our key growth market in the future.”

"Pangaea is a very important distributor in China for our CIE solution,” said Justin Dearborn, Merge CEO. "The quality and cost of the CCD has been well recognized by the market, and Pangaea's wide distribution channel and existing customer base has already shown significant interest in the bundled solution. This is a perfect combination of technologies and marketing channels, and we look forward to bringing more of our technologies to their solution in the future.”

Pangaea, headquartered in Hong Kong, was founded in 1990 as a distribution company offering advanced solutions for telecommunication, healthcare, industrial, and consumer electronics. Pangaea has a broad customer base in China and is currently having eight offices in China offering sales and technical support to customers.

Merge Healthcare develops software solutions that automate healthcare data and diagnostic workflow to create a more comprehensive electronic record of the patient experience.

Related Links:

Merge Healthcare
Pangaea



Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Resorbable Bovine Collagen Membrane
GenDerm
Immobilization System
Cranial 4Pi Immobilization
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.